In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Enanta, Chiron team up a second time for HCV therapeutics

Executive Summary

Enanta Pharmaceuticals (small-molecule anti-infectives) will help Chiron exclusively develop and market its portfolio of protease inhibitors that target enzymes responsible for viral replication of the hepatitis C virus (HCV). Chiron keeps some global (excluding Asia) co-development and marketing rights.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register